{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-051565","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.312455+00:00","generated_at":"2026-06-03T01:27:58.315515+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Geron Q1 net loss $55.4M ($0.09/shr); PDUFA for imetelstat June 16, 2024","bullets":["Q1 net loss of $55.4M ($0.09/shr) vs $38.1M ($0.07/shr) in Q1 2023; revenue $304K.","Cash and marketable securities $465M as of March 31, 2024; $80M principal debt outstanding.","FDA ODAC voted 12-2 in favor of imetelstat benefit/risk for lower-risk MDS; PDUFA date June 16, 2024.","IMpactMF trial timelines extended 6 months: interim analysis now early 2026, final early 2027.","FY2024 total operating expense guidance $270M-$280M; commercial team onboarded in April."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-051565","json":"https://secwatch.observer/filing/0000950170-24-051565.json","markdown":"https://secwatch.observer/filing/0000950170-24-051565.md","text":"https://secwatch.observer/filing/0000950170-24-051565.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017024051565/0000950170-24-051565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017024051565/gern-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:27:58.315515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}